A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus

• ClinicalTrials.gov Identifier: NCT01479881
• Recruitment Status: Completed
• First Posted: November 28, 2011
• Last Update Posted: November 1, 2012
• Sponsor: Tibotec Pharmaceuticals, Ireland
• Information provided by (Responsible Party): Tibotec Pharmaceuticals, Ireland

Study Description

Brief Summary:

The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 (administered once a day) on the single-dose pharmacokinetics of the immunosuppressants cyclosporine and tacrolimus in healthy participants. Cyclosporine and tacrolimus are immunosuppressants used to prevent transplant rejection and may therefore potentially be coadministered with TMC435 in patients infected with hepatitis C virus that undergo liver transplantation. We will also explore the short-term safety and tolerability following coadministration of TMC435 at steady-state and (1) cyclosporine or (2) tacrolimus after single dosing in healthy participants. Steady-state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.

Condition or disease	Intervention/treatment	Phase
Hepatitis C Virus	Drug: tacrolimus; Drug: TMC435; Drug: cyclosporine	Phase 1

Detailed Description:

TMC435 is a protease inhibitor (PI) and is being investigated for treatment of chronic hepatitis C virus (HCV) infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin). This is a Phase I, open-label (both participant and investigator know the name of the medication given at a certain moment) trial in 28 healthy participants to investigate the effect of TMC435 at steady-state on the single dose pharmacokinetics of the immunosuppressants cyclosporine and tacrolimus. The trial population will consist of a total of 28 healthy participants, equally divided over 2 panels. In Panel 1, each participant will receive 2 treatments: a single 100-mg dose of cyclosporine on Day 1 and TMC435 150 mg once daily for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7. In Panel 2, each participant will receive 2 treatments: a single 2-mg dose of tacrolimus on Day 1 and TMC435 150 mg each day for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7. Safety and tolerability will be assessed during the study period and during follow up. Blood and urine safety samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, Day1, Day 2 (only panel 1), Day 7(only panel 2), Day 8 (only panel 2) and at the follow-up visit about 5 to 7 days after last TMC435 intake.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 29 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I, 2-panel, Open-label, Randomized, Cross-over Trial in Healthy Subjects to Investigate the Effect of TMC435 at Steady-state on the Pharmacokinetics of the Immunosuppressants Cyclosporine and Tacrolimus
• Study Start Date: October 2011
• Actual Primary Completion Date: December 2011
• Actual Study Completion Date: December 2011

Arms and Interventions

Arm	Intervention/treatment
Experimental: 001; a single 100-mg dose of cyclosporine, and after a wash out period of at least 10 days, TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7.	Drug: cyclosporine; A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).; Drug: TMC435; TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
Experimental: 002; TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7 and after a wash out period of at least 10 days, a single 100-mg dose of cyclosporine.	Drug: cyclosporine; A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).; Drug: TMC435; TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
Experimental: 003; a single 2-mg dose of tacrolimus on Day 1. After a wash out period of at least 10 days, participants will receive TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7.	Drug: tacrolimus; a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).; Drug: TMC435; TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
Experimental: 004; TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7. After a wash out period of at least 10 days, participants receive a single 2-mg dose of tacrolimus.	Drug: tacrolimus; a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).; Drug: TMC435; TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).

Outcome Measures

Primary Outcome Measures :

1. Change in the steady-state plasma concentration (PK) of cyclosporine and tacrolimus following co-administration with TMC435. [ Time Frame: Measured on Day1 till and including Day 7 for panel 1, and till and including Day 13 for panel 2. Reference is Day 1 for panel 1 and Day 7 for panel 2. ]
   Change in the steady-state plasma PK of cyclosporine and tacrolimus following co-administration with TMC435. PK characteristics of cyclosporine and tacrolimus are determined based on their respective plasma levels at one time point (Day 1 and Day 7 for respectively panel 1 and panel 2) and at 17 other time points. Standard PK parameters such as C0h, Cmin, Cmax, Tmax, AUC24h etc. will be determined.

Secondary Outcome Measures :

1. Number of participants with adverse events as a measure of safety and tolerability when combining TMC435 (150 mg, q.d.) with cyclosporine or tacrolimus. [ Time Frame: Up to Day 50. ]
   to explore the short-term safety and tolerability following coadministration of TMC435 at steady-state and (1) 100-mg dose cyclosporine or (2) 2-mg dose tacrolimus after single dosing in healthy subjects.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Women must be postmenopausal for at least 2 years, OR be surgically sterile, OR be not heterosexually active for the duration of the study or have a vasectomized partner OR if of childbearing potential and heterosexually active, be practicing a highly effective method of birth control before entry, and agree to continue to use the same method of contraception throughout the study and for at least 30 days after the last administration of study drug(s).

Exclusion Criteria:

• A positive Human Immunodeficiency Virus (HIV)-1 or HIV-2 test at screening;
• A positive Hepatitis A, B and C test at screening

Contacts and Locations

Locations

Belgium

Merksem, Belgium

Sponsors and Collaborators

Tibotec Pharmaceuticals, Ireland

Investigators

• Study Director: Tibotec Pharmaceuticals, Ireland Clinical Trial; Tibotec Pharmaceuticals, Ireland

More Information

• Responsible Party: Tibotec Pharmaceuticals, Ireland
• ClinicalTrials.gov Identifier: NCT01479881
• Other Study ID Numbers: CR100686; TMC435-TIDP16-C120 ( Other Identifier: Tibotec Pharmaceuticals, Ireland ); 2011-003021-96 ( EudraCT Number )
• First Posted: November 28, 2011
• Last Update Posted: November 1, 2012
• Last Verified: October 2012

Keywords provided by Tibotec Pharmaceuticals, Ireland:

Hepatitis C Virus; TMC435; TMC435-TiDP16-C120; TMC435-C120; HCV; Hepatitis C; Hep C; Healthy participants

Additional relevant MeSH terms:

Hepatitis C; Hepatitis; Liver Diseases; Digestive System Diseases; Hepatitis, Viral, Human; Virus Diseases; Infections; RNA Virus Infections; Blood-Borne Infections; Communicable Diseases; Flaviviridae Infections; Cyclosporine; Simeprevir; Tacrolimus; Cyclosporins; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Calcineurin Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antifungal Agents; Anti-Infective Agents; Dermatologic Agents; Antirheumatic Agents; Antiviral Agents; Protease Inhibitors